Company intelligence / Profile preview

Chamishi Therapeutics

Deerfield, Illinois, United States

Ownership: Private
Development stage: Other

Overview

Chamishi Therapeutics was founded in 2019 to develop precision antisense oligonucleotide therapies targeting neuroinflammation pathways for Parkinson’s disease patients with GBA mutations and related neurodegenerative diseases, and has reported preclinical optimized ASO candidates generated in collaboration with Q-State Biosciences but no clinical trial results have been disclosed to date.

Therapeutic areas: Neurology
Modalities: Antisense oligonucleotideSynthetic oligonucleotide
Industry: Biotech

Partnerships

Q-State Biosciences (research collaboration to design optimized preclinical antisense oligonucleotide candidates for GBA-Parkinson’s and other neurological disorders)The Silverstein Foundation for Parkinson’s with GBA (co-launching and funding company focused on GBA-Parkinson’s therapies)

Beyond the preview

Go deeper on Chamishi Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chamishi Therapeutics.

Explore the full profile